Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to lower prices of their ...

Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

We sold Novo Nordisk out of the portfolio due to two concerns that made us question the company’s ability to deliver ...

The stock price for Danish drugmaker Novo Nordisk ( NVO 2.06%) is down more than 8% since last Friday's close. What's going ...